Study of Sargramostim in Moderately to Severely Active Crohn's Disease
Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the tolerability, pharmacokinetics and safety of 2 and
6 micro g/kg/day sargramostim administered subcutaneously once daily for 4 weeks, and to
assess the efficacy and safety of 6 micro g/kg/day sargramostim administered subcutaneously
once daily for 8 weeks in comparison with placebo, in patients with moderately to severely
active Crohn's disease.